Skip to content

Salivary biomarker Human Beta Defensins 2 and 3 levels in oral cancer patients

A comparative analysis of Salivary human beta defensin 2 and 3 as a biomarker in diagnosis of Oral potentially malignant disorders and Oral cancer cases. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/05/087963
Enrollment
84
Registered
2025-05-30
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx

Interventions

Intervention1: Nil: Nil

Sponsors

Dr Akanksha Tiwari
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Group 1 Patients having habit of betel quid chewing with areca nut chewing, smoking and smokeless forms of tobacco consumption without any clinical evidence of lesion in oral cavity aged between 20 to 80 years. Group 2 Patients with any inflammatory and infectious oral conditions like moderate to severe periodontitis, ulcers aged between 20 to 80 years. Group 3 Inclusion criteria for Oral Potentially Malignant Disorders- 1 Clinically diagnosed cases of leukoplakia/non homogenous leukoplakia and or erythroplakia with histopathological diagnosis of hyper or para keratosis with or without dysplasia falling withing age group of 20-80 years 2 Clinically diagnosed cases of OSMF falling withing age group of 20-80 years. 3 Clinically and histo-pathologically proven cases of erosive variant of oral lichen planus of patients within age group 20-80 years. Inclusion criteria for oral cancer group- 4 Histopathologically diagnosed cases of Oral squamous cell carcinoma, Invasive carcinoma and carcinoma insitu in patients aged between 20-80 years. Inclusion criteria for control group- Patients with no oral habits of tobacco consumption, patients in good systemic health, not taking any medication for systemic illnesses aged between 20-80 years. Patients who demonstrate good oral hygiene and were free from any oral infection or inflammation like oral ulcers or inflamed gums aged between 20-80 years.

Exclusion criteria

Exclusion criteria: Patients who do not give consent to participate in the study. Patients who have underlying systemic diseases, other malignancies apart from Oral squamous cell carcinoma.

Design outcomes

Primary

MeasureTime frame
The Up regulation and/or down regulation of these salivary defensin biomarkers may validate its efficacy as a useful early screening or diagnostic tool.Timepoint: Outcomes will be assessed quarterly and Final Outcome will be assessed after 18 months

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr Akanksha Tiwari

Manipal College Of Dental Sciences,Manipal

yogesh.chhaparwal@manipal.edu9986454730

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026